Skip to main content
Kringle Pharma,Inc. logo

Kringle Pharma,Inc. — Investor Relations & Filings

Ticker · 4884 ISIN · JP3270790003 T Manufacturing
Open in API
Filings indexed 56 across all filing types
Latest filing 2026-06-10 Share Issue/Capital Cha…
Country JP Japan
Listing T 4884

About Kringle Pharma,Inc.

https://www.kringle-pharma.com/en/

Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on the research and development of regenerative medicines for intractable and rare diseases. The company's core technology is based on recombinant human Hepatocyte Growth Factor (HGF), an endogenous protein with tissue-protective, regenerative, and repairing functions. Kringle Pharma has established a platform to manufacture pharmaceutical-grade HGF protein and is conducting clinical trials for several indications. Key development programs target conditions including acute spinal cord injury, vocal fold scarring, and Amyotrophic Lateral Sclerosis (ALS).

Recent filings

Filing Released Lang Actions
ストックオプション（新株予約権）の発行に関するお知らせ
Share Issue/Capital Change Classification · 95% confidence The document is a Japanese corporate announcement titled “ストックオプション（新株予約権）の発行に関するお知らせ,” detailing the board resolution to issue employee stock acquisition rights (stock options), including terms such as the number of rights, exercise price, exercise period, and dilution impact. This is an announcement of a new share issuance mechanism and constitutes a capital change. According to our filing definitions, this falls under “Share Issue/Capital Change” (Code: SHA).
2026-06-10 Japanese
臨時株主総会招集のための基準日設定に関するお知らせ
Regulatory Filings Classification · 90% confidence The document is a Japanese notification announcing the record date for an extraordinary shareholders’ meeting (“臨時株主総会招集のための基準日設定に関するお知らせ”). It contains no substantive financial statements, ESG details, proxy materials, or post-meeting results—just a regulatory notice setting the record date and meeting schedule. This falls under general regulatory announcements, so it fits the Regulatory Filings (RNS) category.
2026-06-10 Japanese
第三者割当により発行された第16回新株予約権（行使価額修正条項付）の月間行使状況に関するお知らせ
Share Issue/Capital Change Classification · 87% confidence The document is a Japanese corporate announcement detailing the monthly exercise status of the 16th stock acquisition rights (warrants) issued by third-party allotment. It reports on the number of warrants exercised, shares issued, remaining unexercised warrants, exercise prices, and compliance with listing exercise limits. This is not a full financial report but an update on capital changes via new share issuance. Under our taxonomy, this falls under “Share Issue/Capital Change” (SHA).
2026-06-01 Japanese
第三者割当により発行された第16回新株予約権（行使価額修正条項付）の大量行使に関するお知らせ
Share Issue/Capital Change Classification · 95% confidence The document is a corporate notice regarding the large exercise of third-party allocated stock warrants (第16回新株予約権) and the resulting share allotments. It provides detailed figures on warrants exercised, shares issued, and outstanding warrants—typical content for a share issuance and capital structure change announcement. This fits the definition for Share Issue/Capital Change (SHA), not a financial report or other regulatory filing.
2026-05-20 Japanese
2026年９月期 第２四半期決算説明会 質疑応答について
Call Transcript Classification · 87% confidence The document is titled “2026年9月期 第2四半期決算説明会 質疑応答” and contains a question‐and‐answer transcript from the company’s second-quarter earnings presentation. It does not include formal financial statements or an earnings summary but is clearly the verbatim (with minor edits) Q&A from an investor earnings event. This matches the definition of a conference call/presentation transcript rather than a standalone earnings release or interim report.
2026-05-18 Japanese
2026年9月期 第2四半期決算説明会資料
Investor Presentation Classification · 85% confidence The document is a slide deck titled “2026年9月期第2四半期決算説明会” (Q2 FY2026 financial results briefing), containing an agenda, pipeline updates, strategy sections, and references to “決算概況” (financial results overview). It is clearly a presentation prepared for investors (slides, images, pipeline charts, forward‐looking statements), not an official interim report with full financial statements. Therefore, it is classified as an Investor Presentation.
2026-05-14 Japanese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.